The Department of Justice (DOJ) announced this week that ValueAct, activist investment manager, has agreed to pay a record $11 million to settle allegations that it violated the requirements of the Hart-Scott-Rodino Act by improperly relying on the “investment-only” exemption to avoid reporting the transaction and observing the appropriate waiting period.
The settlement stems from ValueAct’s purchases in 2014 and 2015 of stock in two direct competitors, with the intent to participate in those companies’ business decisions, without first complying with the HSR Act’s requirements. As part of the settlement, ValueAct also agreed to injunctive relief designed to prevent future violations.
The complaint details how ValueAct used its access to senior executives of both Halliburton and Baker Hughes to attempt to influence the companies’ proposed merger and other aspects of their businesses. For example, ValueAct executives met frequently with the top executives of the companies and sent numerous e-mails to the executives on a variety of business issues. During these meetings, ValueAct identified specific business areas for improvement and made presentations on post-merger integration.
Full Content: Mondaq
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI